Dilly Suzanne J, Morris George S
ValiSeek Limited, London, United Kingdom.
ValiRx plc, London, United Kingdom.
Curr Drug Discov Technol. 2017;14(2):121-126. doi: 10.2174/1570163814666170117120005.
Drug development has moved along way forward from the days of with doctors peddling cauldrons of herbs and spices, however, the process can still miss opportunities for full exploitation of a drug's potential. Drug reprofiling provides a chance for an established or a forgotten drug to move into a new area of therapy, whether related to the known effects or in a completely new area. In an era of environmental awareness and spiraling costs for traditional drug development, a strategy to squeeze every benefit out of drugs with known safety, tolerability and pharmacological parameters must be a strategically sound desire. We explore examples of success in reprofiling, draw comparisons between techniques, and finally provide two examples from the Valirx plc development pipeline currently undergoing the process.
从医生兜售草药和香料大锅的时代起,药物研发已经取得了长足的进步。然而,这个过程仍然可能错过充分挖掘药物潜力的机会。药物重新定位为一种已上市或被遗忘的药物进入新的治疗领域提供了机会,无论是与已知效应相关的领域还是全新的领域。在一个注重环保且传统药物研发成本不断攀升的时代,一种从具有已知安全性、耐受性和药理学参数的药物中榨取每一项益处的策略必然是一个具有战略合理性的愿望。我们探讨药物重新定位成功的案例,比较不同技术,并最终提供两个来自Valirx plc目前正在进行的研发流程中的例子。